Skip to content
MarketScale
‹ Back to IndustriesHealthcare

A Pulmonary Expert Weighs in on the Johnson & Johnson COVID-19 Vaccine’s Pause

The mission of Health Matters is to promote health equity by elevating the conversation around healthy habits, preventative health, and relevant public health issues. By approaching these topics with an equitable lens, we can all do our part to empower individuals to make more informed decisions about their health and care.   On this episode,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

The mission of Health Matters is to promote health equity by elevating the conversation around healthy habits, preventative health, and relevant public health issues. By approaching these topics with an equitable lens, we can all do our part to empower individuals to make more informed decisions about their health and care.

On this episode, hosts Dr. Jose Medina-Inojosa and Alisa Johnsrud talked with Jonathan Baktari, MD, about the Johnson and Johnson vaccine pause due to potentially fatal blood clots after one American died and one is in critical condition. Baktari is a pulmonary and critical care expert, vaccine expert, CEO of two medical companies —e7Health.com and US Drug Test Centers.

“It’s interesting. The mRNA vaccine has been around for ten years” -Jonathan Baktari, MD

The trio talked about the Johnson and Johnson vaccine and the importance of the other vaccines. Baktari said the vaccine would be part of the solution to get to herd immunity, so even though it’s currently delayed, it will be an essential piece of the puzzle. The Moderna and Pfizer vaccine use mRNA to introduce the virus, while the J&J vaccine uses the adenovirus.

“It’s interesting. The mRNA vaccine has been around for ten years,” Baktari said. He elaborated that nobody had the guts to use mRNA because folks would have been hesitant to inject genetic material. The pandemic, however, forced us to use the technology.

Vaccines have always been a sensitive subject, as some don’t want to use vaccines. For Baktari, he doesn’t understand the hesitancy. He noted that people are still so willing to use antibiotics and other drugs, but they don’t like it when it comes to vaccines. One of the reasons he thinks is because the government advises it.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512